A company briefly owned by Allergan, which recently vowed to limit price hikes on its medicines, is the latest drug maker to be accused of price gouging in the United Kingdom.

From 2008 to mid-2016, Auden Mckenzie raised the price of its generic version of 10 mg hydrocortisone tablets by more than 12,000 percent, compared with cost of a brand-name version that was sold by a different company before the generic came on the market.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Would this argue the UK is getting equal treatment to balance out the reasonable price the UK gets for the product that lead today’s Little?

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy